Itratuf Oral Solution contains Itraconazole 10 mg/ml, a broad-spectrum triazole antifungal agent indicated for the treatment of various fungal infections. Itraconazole exerts its antifungal effect by inhibiting the cytochrome P450-dependent enzyme lanosterol 14-α-demethylase, which is essential for ergosterol synthesis, a critical component of fungal cell membranes. This disruption leads to increased membrane permeability and ultimately fungal cell death. Itratuf Oral Solution is effective against a wide range of pathogenic fungi, including dermatophytes, yeasts such as Candida species, and molds like Aspergillus. It is commonly prescribed for conditions such as onychomycosis, cutaneous and subcutaneous mycoses, blastomycosis, histoplasmosis, and other systemic fungal infections. The oral solution formulation allows for flexible dosing and improved bioavailability, particularly in patients with swallowing difficulties or those requiring precise dose adjustments. Itratuf should be administered with food to enhance absorption. Caution is advised in patients with hepatic impairment, congestive heart failure, or those taking concomitant medications metabolized by cytochrome P450 enzymes due to potential drug interactions. Regular monitoring of liver function and clinical response is recommended during therapy. Itratuf Oral Solution should be used under medical supervision to ensure safety and efficacy.